Cataplexy Market: Industry Analysis, Epidemiology, Leading Companies, Pipeline Drugs and Competitive Analysis by DelveInsight | Axsome Therapeutics, Takeda, Avadel, Others

Cataplexy Market: Industry Analysis, Epidemiology, Leading Companies, Pipeline Drugs and Competitive Analysis by DelveInsight | Axsome Therapeutics, Takeda, Avadel, Others

“Cataplexy Market”

Cataplexy is a sudden and uncontrollable muscle weakness or paralysis that comes on during the day and is often triggered by a strong emotion, such as excitement or laughter. The vast majority of people who experience cataplexy do so as a result of having type 1 narcolepsy, a chronic sleep and neurological disorder in which the brain has trouble properly controlling wake and sleep cycles. In very rare cases, cataplexy has been reported in individuals without narcolepsy. The cause of this circumstance remains unknown.

 

DelveInsight’s Cataplexy Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Cataplexy, historical and forecasted epidemiology as well as the Cataplexy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some facts of Cataplexy Market are:

  • Mirabile and Sharma (2020) in the study titled “Cataplexy”, stated that in the US, narcolepsy affects 1 in 2000 individuals with an equal distribution amongst the sexes. As per the study, symptom onset most frequently occurs during adolescence; however, diagnosis often gets delayed on average by 15 years. The study also highlights that there are two forms of narcolepsy, namely, type 1 which is associated with cataplexy while this feature is absent in type 2.
  • In the US, type 1 narcolepsy affects 1 to 2 in 4000 individuals.
  • The study titled “The Prevalence and Characteristics of Primary Headache and Dream-Enacting Behaviour in Japanese Patients with Narcolepsy or Idiopathic Hypersomnia: A Multi-Centre Cross-Sectional Study” by Suzuki et al., (2015) suggested that the prevalence of narcolepsy with cataplexy has been estimated to range from 0.16% to 0.18% in Japan, while narcolepsy without cataplexy represents from 15% to 25% of the clinical narcoleptic population.
  • The prevalence of cataplexy has been reported in up to 29% of young adults with associated excessive daytime sleepiness. However, the prevalence of isolated cataplexy is unknown.
  • Secondary cataplexy refers to the characteristic episodes of sudden muscle weakness that are caused by an underlying health condition.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/cataplexy-market

 

Scope of Cataplexy Market Report:

  • The report covers the descriptive overview of Cataplexy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Cataplexy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Cataplexy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Cataplexy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Cataplexy market

 

Cataplexy can cause muscle weakness in any part of the body, though it commonly affects the limbs (hands may drop whatever they’re holding, knees may buckle, legs may collapse) and face (eyelids may droop, jaw may go slack and speech become slurred, the head may nod). The attacks can range from mild, such as a slight drooping of the eyelids, to severe, such as a total body collapse. Symptoms of cataplexy associated with narcolepsy often begin in childhood and young adulthood, between the ages of 7 and 25 years, but it can start at any time.

 

Request for Sample Report: https://www.delveinsight.com/sample-request/cataplexy-market

 

Cataplexy Companies covered are:

  • Axsome Therapeutics
  • Suven Life Sciences
  • Takeda
  • Avadel
  • And Many Others

 

Cataplexy Therapies are:

  • AXS-12
  • SUVN-G3031
  • Tak-944
  • TAK-925
  • FT218
  • And Many Others

 

Request for Sample Report: https://www.delveinsight.com/sample-request/cataplexy-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Central Nervous System Lymphoma

3. Competitive Intelligence Analysis for Central Nervous System Lymphoma

4. Central Nervous System Lymphoma: Market Overview at a Glance

5. Central Nervous System Lymphoma: Disease Background and Overview

5.1. Introduction

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Central Nervous System Lymphoma Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Central Nervous System Lymphoma: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Central Nervous System Lymphoma

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

 

About DelveInsight

DelveInsight is a premier Business Consulting and Market Research firm focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/cataplexy-market